Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes mellitus
• Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic drug) mono-therapy
• HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.5-9.5% (both inclusive)
• Body mass index (BMI) between 27-40 kg/m^2 (both inclusive)
• Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight)
• Euthyroid subjects
• Subjects should be unrestrained eaters

Exclusion Criteria:

• Recurrent severe hypoglycaemia
• Impaired liver function
• Impaired renal function
• Cardiac problems
• Uncontrolled treated/untreated hypertension
• Known or suspected allergy to trial products or related products
• Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight
• Active hepatitis B and/or active hepatitis C
• Positive HIV (human immunodeficiency virus) antibodies
• Known or suspected abuse of alcohol or narcotics
• Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator